PRA Health Sciences provides various product development services for pharmaceutical and biotechnology companies worldwide. The company was founded in 1976 and is based in Raleigh, North Carolina.
PRAH Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for PRA Health Sciences Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that PRA Health Sciences Inc ranked in the 57th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. The most interesting components of our discounted cash flow analysis for PRA Health Sciences Inc ended up being:
In the past 4.7 years, PRA Health Sciences Inc has a compound free cash flow growth rate of 0.28%; that's better than 62.74% of cash flow producing equities in the Healthcare sector, where it is classified.
PRA Health Sciences Inc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than merely 24.81% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of PRA Health Sciences Inc? See HBIO, CHE, JAZZ, SNY, and UTHR.
ReportsnReports.com the exclusive leading provider of market research reports published research report on “China Contract Research Organization (CRO) Market (Clinical, Pre-clinical & Discovery): Insights, Trends and Forecast (2020-2024)”. China CRO market value is anticipated to reach US$27.04 billion in 2024, growing
PRA’s remote patient monitoring (RPM) solution now offers a suite of COVID-19 tools – diagnostic testing, clinical monitoring, and symptom reporting and management functionalityRALEIGH, N.C., Dec. 17, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences (NASDAQ: PRAH) announced today the enhancement of its COVID-19 Monitoring Program with the addition of at-home COVID-19 testing capabilities. Enabled through a collaboration with PWNHealth and Fulgent Genetics (NASDAQ: FLGT), the testing capabilities expand PRA’s existing COVID-19 clinical monitoring, symptom reporting and management services that are available on the patient-facing Health HarmonyTM mobile app. Patients are supported throughout their COVID-19 journey – from education, exposure, testing and monitoring through recovery. “Getting ...